Traws Pharma, Inc. (TRAW): R&D Expense
$12.14M
Year ended 2025-12-31
$13.36M
Trailing 12 months to 2026-06-30
+2.1%
3-year compound annual growth
-6.4%
5-year compound annual growth
-7.3%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.14M | -5.5% | 2026-04-15, From 2025-01-01 |
| 2024-12-31 | $12.85M | +12.4% | 2026-04-15, From 2024-01-01 |
| 2023-12-31 | $11.43M | +0.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $11.41M | +56.3% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $7.30M | -56.8% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $16.90M | +8.8% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $15.54M | -8.2% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $16.92M | -11.5% | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | $19.12M | -4.7% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $20.07M | -22.5% | 2018-03-16, From 2016-01-01 |
| 2015-12-31 | $25.89M | -47.6% | 2017-03-29, From 2015-01-01 |
| 2014-12-31 | $49.42M | -1.5% | 2016-03-28, From 2014-01-01 |
| 2013-12-31 | $50.18M | -4.9% | 2015-03-30, From 2013-01-01 |
| 2012-12-31 | $52.76M | +133.2% | 2015-03-30, From 2012-01-01 |
| 2011-12-31 | $22.62M | n/a | 2014-03-20, From 2011-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | 2025-12-31 | $12.14M | -5.5% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | 2025-12-31 | $4.05M | +12.0% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $11.51M | -28.6% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $368.2K | -52.2% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $1.72M | -48.0% |
| Genprex, Inc. (GNPX) | 2025-12-31 | $9.43M | -10.5% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $6.80M | -68.4% |
| Oragenics Inc (OGEN) | 2025-12-31 | $2.39M | -41.8% |
Compare TRAW, SHPH, LGVN, LTRN side by side · Screen every company in Pharmaceutical Preparations ↗